CL2011002972A1 - Compuestos derivados de imidazol sustituido, moduladores de la actividad de receptores x del higado (lxr); composicion farmaceutica, utiles en el tratamiento de trastornos como aterosclerosis, resistencia a la insulina, artrosis, diabetes, enfermedad de alzheimer, entre otras. - Google Patents
Compuestos derivados de imidazol sustituido, moduladores de la actividad de receptores x del higado (lxr); composicion farmaceutica, utiles en el tratamiento de trastornos como aterosclerosis, resistencia a la insulina, artrosis, diabetes, enfermedad de alzheimer, entre otras.Info
- Publication number
- CL2011002972A1 CL2011002972A1 CL2011002972A CL2011002972A CL2011002972A1 CL 2011002972 A1 CL2011002972 A1 CL 2011002972A1 CL 2011002972 A CL2011002972 A CL 2011002972A CL 2011002972 A CL2011002972 A CL 2011002972A CL 2011002972 A1 CL2011002972 A1 CL 2011002972A1
- Authority
- CL
- Chile
- Prior art keywords
- disorders
- lxr
- atherosclerosis
- alzheimer
- modulators
- Prior art date
Links
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 102000004311 liver X receptors Human genes 0.000 title abstract 3
- 108090000865 liver X receptors Proteins 0.000 title abstract 3
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 title abstract 2
- 206010022489 Insulin Resistance Diseases 0.000 title abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 2
- 208000035475 disorder Diseases 0.000 title abstract 2
- 230000000694 effects Effects 0.000 title abstract 2
- 201000008482 osteoarthritis Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title abstract 2
- 150000002460 imidazoles Chemical class 0.000 title 1
- 201000004681 Psoriasis Diseases 0.000 abstract 2
- 206010008190 Cerebrovascular accident Diseases 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- RAXXELZNTBOGNW-UHFFFAOYSA-O Imidazolium Chemical compound C1=C[NH+]=CN1 RAXXELZNTBOGNW-UHFFFAOYSA-O 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 230000037365 barrier function of the epidermis Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000026106 cerebrovascular disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000006870 function Effects 0.000 abstract 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 208000002780 macular degeneration Diseases 0.000 abstract 1
- 230000015654 memory Effects 0.000 abstract 1
- 230000006984 memory degeneration Effects 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18173609P | 2009-05-28 | 2009-05-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2011002972A1 true CL2011002972A1 (es) | 2012-08-17 |
Family
ID=43223342
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2011002972A CL2011002972A1 (es) | 2009-05-28 | 2011-11-24 | Compuestos derivados de imidazol sustituido, moduladores de la actividad de receptores x del higado (lxr); composicion farmaceutica, utiles en el tratamiento de trastornos como aterosclerosis, resistencia a la insulina, artrosis, diabetes, enfermedad de alzheimer, entre otras. |
Country Status (31)
| Country | Link |
|---|---|
| US (4) | US8618154B2 (enExample) |
| EP (1) | EP2435410B1 (enExample) |
| JP (1) | JP5625050B2 (enExample) |
| KR (1) | KR101676704B1 (enExample) |
| CN (1) | CN102648184B (enExample) |
| AR (1) | AR078049A1 (enExample) |
| AU (1) | AU2010254082B2 (enExample) |
| BR (1) | BRPI1013259B8 (enExample) |
| CA (1) | CA2761934C (enExample) |
| CL (1) | CL2011002972A1 (enExample) |
| CO (1) | CO6470826A2 (enExample) |
| CY (1) | CY1119407T1 (enExample) |
| DK (1) | DK2435410T3 (enExample) |
| EA (1) | EA019960B1 (enExample) |
| ES (1) | ES2620451T3 (enExample) |
| HR (1) | HRP20170194T1 (enExample) |
| IL (1) | IL216176A (enExample) |
| LT (1) | LT2435410T (enExample) |
| MX (1) | MX2011012559A (enExample) |
| MY (1) | MY153958A (enExample) |
| NZ (1) | NZ596330A (enExample) |
| PE (1) | PE20120797A1 (enExample) |
| PL (1) | PL2435410T3 (enExample) |
| PT (1) | PT2435410T (enExample) |
| SG (1) | SG176247A1 (enExample) |
| SI (1) | SI2435410T1 (enExample) |
| SM (1) | SMT201700253T1 (enExample) |
| TN (1) | TN2011000585A1 (enExample) |
| TW (1) | TWI488844B (enExample) |
| WO (1) | WO2010138598A2 (enExample) |
| ZA (1) | ZA201108181B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2435410T3 (da) * | 2009-05-28 | 2017-04-10 | Exelixis Patent Co Llc | LXR-modulatorer |
| AR088728A1 (es) | 2011-03-25 | 2014-07-02 | Bristol Myers Squibb Co | Moduladores de lxr como prodroga de imidazol |
| HUE040231T2 (hu) | 2012-03-02 | 2019-02-28 | Ralexar Therapeutics Inc | Máj X receptor (LXR) modulátorok bõrbetegségek, rendellenességek és állapotok kezelésére |
| EP3626309B1 (en) | 2012-08-13 | 2023-03-08 | The Rockefeller University | Lxrbeta agonist for the treatment of cancer |
| ES2694001T3 (es) | 2013-03-15 | 2018-12-17 | Bristol-Myers Squibb Company | Moduladores de LXR |
| WO2014144037A1 (en) * | 2013-03-15 | 2014-09-18 | Bristol-Myers Squibb Company | Lxr modulators |
| US9981913B2 (en) | 2013-09-04 | 2018-05-29 | Ralexar Therapeutics, Inc. | Liver X receptor (LXR) modulators |
| CN110003108A (zh) | 2013-09-04 | 2019-07-12 | 瑞雷克萨治疗公司 | 肝脏x受体（lxr）调节剂 |
| WO2015106164A1 (en) | 2014-01-10 | 2015-07-16 | Rgenix, Inc. | Lxr agonists and uses thereof |
| KR101815734B1 (ko) | 2015-05-29 | 2018-01-05 | 가톨릭대학교 산학협력단 | ｍｉＲ－７, ｍｉＲ－１８ａ 또는 ｍｉＲ－１８ｂ를 유효성분으로 포함하는 대사성 질환의 예방 또는 치료용 약학적 조성물 |
| CA3010883A1 (en) | 2016-01-11 | 2017-07-20 | The Rockefeller University | Methods for the treatment of myeloid derived suppressor cells related disorders |
| AU2018373028A1 (en) | 2017-11-21 | 2020-04-30 | Inspirna, Inc. | Polymorphs and uses thereof |
| EP3999055A1 (en) | 2019-07-15 | 2022-05-25 | Novartis AG | Methods for treating meibomian gland dysfunction with liver x receptor agonists |
| CN110305141B (zh) * | 2019-07-18 | 2022-01-11 | 深圳市三启药物开发有限公司 | 一种螺(3,3’-异丙基吡咯烷氧化吲哚)类肝x受体调节剂及其制备方法和应用 |
| WO2021119397A1 (en) | 2019-12-13 | 2021-06-17 | Rgenix, Inc. | Metal salts and uses thereof |
| CN115656401B (zh) * | 2022-11-09 | 2025-03-28 | 武汉海特生物创新医药研究有限公司 | 一种咪唑-4-甲酸乙酯纯度的hplc检测方法 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4231938A (en) | 1979-06-15 | 1980-11-04 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
| US4444784A (en) | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
| DK149080C (da) | 1980-06-06 | 1986-07-28 | Sankyo Co | Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre |
| WO1984002131A1 (fr) | 1982-11-22 | 1984-06-07 | Sandoz Ag | Produits analogues de mevalolactone et leurs derives, leurs procedes de production, compositions pharmaceutiques les contenant ainsi que leur utilisation en tant que produits pharmaceutiques |
| US5354772A (en) | 1982-11-22 | 1994-10-11 | Sandoz Pharm. Corp. | Indole analogs of mevalonolactone and derivatives thereof |
| FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| US5177080A (en) | 1990-12-14 | 1993-01-05 | Bayer Aktiengesellschaft | Substituted pyridyl-dihydroxy-heptenoic acid and its salts |
| WO1993006215A1 (en) | 1991-09-17 | 1993-04-01 | The Salk Institute For Biological Studies | Receptor of the thyroid/steroid hormone receptor superfamily |
| PL334840A1 (en) | 1997-01-24 | 2000-03-27 | Univ California | Application of fxr, pparalpha and lxralpha activators in order to restore the barrier function, to stimulate epithelium differentation and to inhibit proliferation |
| AU5994199A (en) | 1998-09-23 | 2000-04-10 | Alexander Mata De Urquiza | Analysis of ligand activated nuclear receptors (in vivo) |
| EP1140079B1 (en) | 1998-12-23 | 2009-06-03 | Glaxo Group Limited | Assays for ligands for nuclear receptors |
| ATE330632T1 (de) | 1999-03-26 | 2006-07-15 | Hope City | Selektion von fxr-rezeptormodulatoren |
| WO2000078972A2 (en) | 1999-06-18 | 2000-12-28 | Cv Therapeutics, Inc. | Regulation with binding cassette transporter protein abc1 |
| WO2001082917A2 (en) | 2000-05-03 | 2001-11-08 | Tularik Inc. | Treatment of hypertriglyceridemia and other conditions using lxr modulators |
| US6924311B2 (en) | 2001-10-17 | 2005-08-02 | X-Ceptor Therapeutics, Inc. | Methods for affecting various diseases utilizing LXR compounds |
| US7482366B2 (en) * | 2001-12-21 | 2009-01-27 | X-Ceptor Therapeutics, Inc. | Modulators of LXR |
| WO2004011446A1 (en) * | 2002-07-26 | 2004-02-05 | Bayer Pharmaceuticals Corporation | Indane, dihydrobenzofuran, and tetrahydronaphthalene carboxylic acid derivatives and their use as antidiabetics |
| TWI324596B (en) * | 2002-08-26 | 2010-05-11 | Nat Health Research Institutes | Imidazolamino compounds |
| US7534805B2 (en) * | 2003-05-27 | 2009-05-19 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Imidazole derivatives, their preparation and their use as medicaments |
| JP5095216B2 (ja) * | 2003-11-14 | 2012-12-12 | ローラス セラピューティクス インコーポレーテッド | アリールイミダゾールおよびその抗癌剤としての使用 |
| AU2005211809B2 (en) * | 2004-02-11 | 2009-02-12 | Irm Llc | Compounds and compositions as LXR modulators |
| CN101248048B (zh) * | 2005-06-27 | 2013-08-28 | 埃克塞利希斯专利有限责任公司 | 吡唑基lxr调节剂 |
| MX2008000141A (es) * | 2005-06-27 | 2008-04-07 | Exelixis Inc | Moduladores de lxr basados en imidazol. |
| EP2121621B1 (en) | 2006-12-08 | 2014-05-07 | Exelixis Patent Company LLC | Lxr and fxr modulators |
| DK2435410T3 (da) * | 2009-05-28 | 2017-04-10 | Exelixis Patent Co Llc | LXR-modulatorer |
-
2010
- 2010-05-26 DK DK10721902.4T patent/DK2435410T3/da active
- 2010-05-26 EP EP10721902.4A patent/EP2435410B1/en active Active
- 2010-05-26 ES ES10721902.4T patent/ES2620451T3/es active Active
- 2010-05-26 BR BRPI1013259A patent/BRPI1013259B8/pt not_active IP Right Cessation
- 2010-05-26 LT LTEP10721902.4T patent/LT2435410T/lt unknown
- 2010-05-26 US US13/319,937 patent/US8618154B2/en active Active
- 2010-05-26 EA EA201171488A patent/EA019960B1/ru not_active IP Right Cessation
- 2010-05-26 PT PT107219024T patent/PT2435410T/pt unknown
- 2010-05-26 SI SI201031427A patent/SI2435410T1/sl unknown
- 2010-05-26 SM SM20170253T patent/SMT201700253T1/it unknown
- 2010-05-26 PE PE2011002005A patent/PE20120797A1/es active IP Right Grant
- 2010-05-26 MY MYPI2011006278A patent/MY153958A/en unknown
- 2010-05-26 CA CA2761934A patent/CA2761934C/en active Active
- 2010-05-26 PL PL10721902T patent/PL2435410T3/pl unknown
- 2010-05-26 HR HRP20170194TT patent/HRP20170194T1/hr unknown
- 2010-05-26 KR KR1020117031397A patent/KR101676704B1/ko not_active Expired - Fee Related
- 2010-05-26 SG SG2011087459A patent/SG176247A1/en unknown
- 2010-05-26 JP JP2012513215A patent/JP5625050B2/ja not_active Expired - Fee Related
- 2010-05-26 MX MX2011012559A patent/MX2011012559A/es active IP Right Grant
- 2010-05-26 NZ NZ596330A patent/NZ596330A/xx unknown
- 2010-05-26 AU AU2010254082A patent/AU2010254082B2/en not_active Ceased
- 2010-05-26 CN CN201080033601.2A patent/CN102648184B/zh not_active Expired - Fee Related
- 2010-05-26 WO PCT/US2010/036211 patent/WO2010138598A2/en not_active Ceased
- 2010-05-28 AR ARP100101870A patent/AR078049A1/es not_active Application Discontinuation
- 2010-05-28 TW TW099117252A patent/TWI488844B/zh not_active IP Right Cessation
-
2011
- 2011-11-07 IL IL216176A patent/IL216176A/en active IP Right Grant
- 2011-11-08 ZA ZA2011/08181A patent/ZA201108181B/en unknown
- 2011-11-16 TN TNP2011000585A patent/TN2011000585A1/en unknown
- 2011-11-24 CL CL2011002972A patent/CL2011002972A1/es unknown
- 2011-11-25 CO CO11161736A patent/CO6470826A2/es active IP Right Grant
-
2013
- 2013-11-21 US US14/085,926 patent/US20140163081A1/en not_active Abandoned
-
2015
- 2015-05-04 US US14/703,247 patent/US20150299136A1/en not_active Abandoned
-
2016
- 2016-06-07 US US15/175,425 patent/US20160280661A1/en not_active Abandoned
-
2017
- 2017-04-05 CY CY20171100403T patent/CY1119407T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2011002972A1 (es) | Compuestos derivados de imidazol sustituido, moduladores de la actividad de receptores x del higado (lxr); composicion farmaceutica, utiles en el tratamiento de trastornos como aterosclerosis, resistencia a la insulina, artrosis, diabetes, enfermedad de alzheimer, entre otras. | |
| CO6480918A2 (es) | Antagonistas policíclicos de receptores de ácido lisofosfatídico. | |
| CO6771417A2 (es) | Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis | |
| PA8660801A1 (es) | Anticuerpos antiamiloides humanizados | |
| BR112012013431A8 (pt) | composto, composição farmacêutica e seu uso | |
| CR11854A (es) | Compuestos de piridina | |
| CL2011002430A1 (es) | Variante de peptido natriuretico de tipo c (cnp); composicion farmaceutica que la comprende; metodo de produccion, celula huesped y uso de dicha variante. | |
| UY32923A (es) | Compuestos policíclicos como antagonistas del receptor de ácido lisofosfatídico | |
| BR112014026952A8 (pt) | derivados de aminopirimidina pirazol, seus usos, e composição | |
| CO2017003070A2 (es) | Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrógenos y usos de los mismos | |
| BR112013006395A2 (pt) | moduladores do receptor de estrogênio e seus usos. | |
| AR091000A1 (es) | Polipeptidos de union a receptores de quimiocinas | |
| CL2012000620A1 (es) | Formulaciones farmaceuticas de un anticuerpo anti cd-20; uso de la formulacion para tratar enfermedad o trastorno que pueda corregirse mediante tratamiento con anticuerpo anti-cd20. | |
| CO6612199A2 (es) | Pèptidos tau antigènicos y usos de los mismos | |
| CL2008002787A1 (es) | Compuestos derivados de piperidina, que presentan actividad moduladora sobre la actividad del receptor gpr 119; composición farmacéutica que comprende a dichos compuestos; y su uso en el tratamiento de enfermedades tales como diabetes tipo 1 y 2, hiperllpidemia, enfermedad coronaria, obesidad y disfuncion erectil. | |
| CR20110466A (es) | Anticuerpos biespecíficos anti-erbb-3/anti-c-met | |
| UY32327A (es) | Antagonistas de receptores de ácido lisofosfatídico | |
| BR112015015468B8 (pt) | Composto, e, composição farmacêutica | |
| GT200600297A (es) | Nuevos anticuerpos anti-madcam | |
| ECSP055699A (es) | Indazoles, benzotiazoles y benzoisotiazoles, y su preparacion y usos | |
| CL2015000717A1 (es) | Compuestos derivados de piridinonas biciclicas y sus sales; composicion farmaceutica que los comprende; y su uso para el tratamiento de la neurodegeneracion y trastornos psiquiatricos, que incluyen enfermedad de alzheimer o enfermedad de niemann-pick tipo c. | |
| NI201400123A (es) | Agentes para tratar trastornos que implican la modulación de receptores de rianodina | |
| CL2008002506A1 (es) | Compuestos derivados de bencimidazol sustituido, procedimiento de preparacion, composicion farmaceutica, util en el tratamiento de enfermedades moduladas con antagonistas del receptor fxr, en particular para el tratamiento de los niveles incrementados de lipidos y/o colesterol, enfermedad aterosclerotica, diabetes, cancer, parkinson, alzheimer. | |
| UY32944A (es) | Compuestos poliméricos de ésteres silil benzoicos, sus usos y composiciones | |
| CO6351778A2 (es) | Acidos naftilaceticos |